Gilead's Trodelvy-Keytruda Combo Gains CHMP Nod for Metastatic TNBC
Event summary
- CHMP recommends approval of Trodelvy plus Keytruda for PD-L1-positive first-line metastatic TNBC in Europe.
- Phase 3 ASCENT-04/KEYNOTE-D19 study showed a 35% reduced risk of disease progression or death.
- European Commission decision expected later in 2026; U.S. FDA already approved the combination.
The big picture
Gilead's CHMP recommendation strengthens its leadership in metastatic TNBC, a high-unmet-need indication. The approval expands the use of Trodelvy beyond monotherapy, reinforcing Gilead's strategy to dominate in aggressive breast cancer treatments. With over 75,000 patients treated since 2020, Trodelvy's success could drive further adoption in other high Trop-2 expression cancers.
What we're watching
- Regulatory Timing
- Whether the European Commission will finalize approval by year-end, accelerating Gilead's market access.
- Commercial Strategy
- How Gilead positions Trodelvy-Keytruda against existing TNBC treatments in Europe and the U.S.
- Pipeline Expansion
- The pace at which Gilead advances other Trop-2-directed ADC candidates in ongoing trials.